REFRACTORY WALDENSTROM MACROGLOBULINEMIA
Clinical trials for REFRACTORY WALDENSTROM MACROGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY WALDENSTROM MACROGLOBULINEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY WALDENSTROM MACROGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer drug combo trial halted early: what it means for patients
Disease control TerminatedThis study tested a combination of two drugs, ibrutinib and ixazomib, in 21 people with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see if the combo could shrink or control the cancer. The trial was stopped early, so results are limited, but the approach a…
Matched conditions: REFRACTORY WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental drug pomalidomide tested in rare blood cancer
Disease control TerminatedThis early-phase trial tested the drug pomalidomide in 15 people with Waldenstrom macroglobulinemia, a rare blood cancer that had returned or was not responding to prior treatments. The goal was to find the safest dose and see how the drug affects the immune system and cancer gro…
Matched conditions: REFRACTORY WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 14:07 UTC